A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

Trial Profile

A Phase 2a, Dose-Escalation, Open-Label Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease

Recruiting
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2018

At a glance

  • Drugs KD 025 (Primary)
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Kadmon Corporation
  • Most Recent Events

    • 22 Feb 2018 In October 2017, KD025 received orphan drug designation from the U.S. Food and Drug Administration for cGVHD, as reported in a Kadmon media release.
    • 22 Feb 2018 According to a Kadmon Holdings media release, results of this trial are being presented in an oral presentation at the BMT Tandem Meetings 2018.
    • 22 Feb 2018 Results published in the Kadmon Corporation Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top